Studies support antimicrobial properties of AMS silver alginate
20 July 2011
Advanced Medical Solutions Group plc has announced that two further clinical studies
have recently been published, targeted to help drive continued growth in
AMS’s key silver alginate woundcare business.
The studies, which were published in both The International Wound
Journal and the Journal of Woundcare, demonstrate the antimicrobial
efficacy of one of AMS’s commercialised silver alginate dressings in
killing 160 chronic and burn wound microorganisms, including 29 strains
of the superbug Methicillin-resistant Staphylococcus Aureus (MRSA).
Chris Meredith, Chief Executive
Officer of AMS stated: “We are very pleased with the efficacy results
for our silver alginate woundcare products, which continue to prove
effective against MRSA, one of the most problematic infections to treat.
Our quality silver alginate products, coupled with supporting clinical
evidence such as these latest studies, have helped our partners
successfully capture 20% of the US$230 million global antimicrobial
fibre market in the last five years. We look forward to continued
success in this area.”
Source: AMS Group plc